Second-line hope: regorafenib tested after lenvatinib failure in liver cancer
NCT ID NCT07514429
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug regorafenib can help people with advanced liver cancer whose disease got worse after treatment with lenvatinib. About 24 adults will receive regorafenib and be monitored for how long their cancer stays under control and for side effects. The goal is to see if this second treatment can slow the cancer's growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple belly press make liver cancer radiation more precise?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Home hospital care for infections: when does it fail?
- Virus hunts liver tumors before chemo strikes
- New combo therapy aims to stop liver cancer from coming back